- Home
- BCAT vs AVDL Comparison
BCAT vs AVDL Comparison
Compare BCAT & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAT
- AVDL
- Stock Information
- Founded
- BCAT 2020
- AVDL 2015
- Country
- BCAT United States
- AVDL Ireland
- Employees
- BCAT N/A
- AVDL N/A
- Industry
- BCAT Finance/Investors Services
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- BCAT Finance
- AVDL Health Care
- Exchange
- BCAT Nasdaq
- AVDL Nasdaq
- Market Cap
- BCAT 1.5B
- AVDL 1.5B
- IPO Year
- BCAT N/A
- AVDL 1996
- Fundamental
- Price
- BCAT $14.54
- AVDL $18.82
- Analyst Decision
- BCAT
- AVDL Buy
- Analyst Count
- BCAT 0
- AVDL 10
- Target Price
- BCAT N/A
- AVDL $18.94
- AVG Volume (30 Days)
- BCAT 308.8K
- AVDL 4.6M
- Earning Date
- BCAT 01-01-0001
- AVDL 11-12-2025
- Dividend Yield
- BCAT 9.38%
- AVDL N/A
- EPS Growth
- BCAT N/A
- AVDL N/A
- EPS
- BCAT 1.43
- AVDL N/A
- Revenue
- BCAT N/A
- AVDL $221,075,000.00
- Revenue This Year
- BCAT N/A
- AVDL $64.21
- Revenue Next Year
- BCAT N/A
- AVDL $30.80
- P/E Ratio
- BCAT $11.41
- AVDL N/A
- Revenue Growth
- BCAT N/A
- AVDL 132.35
- 52 Week Low
- BCAT $13.67
- AVDL $6.38
- 52 Week High
- BCAT $16.38
- AVDL $18.95
- Technical
- Relative Strength Index (RSI)
- BCAT 43.56
- AVDL 79.92
- Support Level
- BCAT $14.35
- AVDL $13.83
- Resistance Level
- BCAT $14.70
- AVDL $18.95
- Average True Range (ATR)
- BCAT 0.14
- AVDL 0.51
- MACD
- BCAT 0.01
- AVDL 0.30
- Stochastic Oscillator
- BCAT 33.33
- AVDL 97.44
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.